Organon

Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator

Retrieved on: 
土曜日, 7月 1, 2023
Medical Supplies, Medical Devices, Health, Clinical Trials, Pharmaceutical, Biotechnology, SB5, Infection, TNF, Arthritis, Hospital, TB, Organon & Co., Lymphoma, Intuition, Ankylosing spondylitis, Multimedia, Medicine, HCP, Ulcerative colitis, Psoriasis, Sepsis, Malignancy, Juvenile idiopathic arthritis, End-use certificate, Acquisition, Patient, Tuberculosis, Risk, Adolescence, Certification, Death, NYSE, Rheumatoid arthritis, Syringe, Pharmaceutical industry, Generic drug, Adalimumab, Organon

Organon & Co. (NYSE: OGN) & Samsung Bioepis Co., Ltd. today announced that HADLIMA™ (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab), is now available to patients in the United States.

Key Points: 
  • Organon & Co. (NYSE: OGN) & Samsung Bioepis Co., Ltd. today announced that HADLIMA™ (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab), is now available to patients in the United States.
  • Consistent with Humira, HADLIMA is available in both citrate-free high concentration (100 mg/mL) and citrate-containing low concentration (50 mg/mL) to provide patients with seamless continuity of care.
  • “We are thrilled to now provide HADLIMA in the US at a more affordable cost and expand much-needed access to adalimumab.
  • Each registered nurse will also be certified as a health coach to provide an experience tailored to fit the unique needs of each patient.

Vesalius Biocapital Announces First Close of Fourth Fund Raising EUR 95 Million

Retrieved on: 
木曜日, 6月 29, 2023
European Investment Fund, Sword Health, Drug development, Lead, Medicine, Science, Investment, Initial public offering, Astellas Pharma, Pharmaceutical industry, Andreas Vesalius, Organon

STRASSEN, Luxembourg, June 29, 2023 /PRNewswire/ -- Vesalius Biocapital, the specialist life sciences venture capital investor, announces the first close of its fourth fund, Vesalius Biocapital IV, securing over €95 million of commitments.

Key Points: 
  • STRASSEN, Luxembourg, June 29, 2023 /PRNewswire/ -- Vesalius Biocapital, the specialist life sciences venture capital investor, announces the first close of its fourth fund, Vesalius Biocapital IV, securing over €95 million of commitments.
  • Starting immediately Vesalius Biocapital IV is to invest in first and best-in-class European life science companies in drug development and digital health.
  • Commenting on the first close, Stéphane Verdood, Managing Partner at Vesalius Biocapital IV said:
    "Our successful track record placed us in a strong position to attract high quality investors such as the EIF (European Investment Fund) to Vesalius Biocapital IV.
  • Vesalius Biocapital IV is targeting €150M and will accept new investors on a "rolling closing" basis until the final closing in 2024.

Vesalius Biocapital Announces First Close of Fourth Fund Raising EUR 95 Million

Retrieved on: 
木曜日, 6月 29, 2023
European Investment Fund, Sword Health, Drug development, Lead, Medicine, Science, Investment, Initial public offering, Astellas Pharma, Pharmaceutical industry, Andreas Vesalius, Organon

STRASSEN, Luxembourg, June 29, 2023 /PRNewswire/ -- Vesalius Biocapital, the specialist life sciences venture capital investor, announces the first close of its fourth fund, Vesalius Biocapital IV, securing over €95 million of commitments.

Key Points: 
  • STRASSEN, Luxembourg, June 29, 2023 /PRNewswire/ -- Vesalius Biocapital, the specialist life sciences venture capital investor, announces the first close of its fourth fund, Vesalius Biocapital IV, securing over €95 million of commitments.
  • Starting immediately Vesalius Biocapital IV is to invest in first and best-in-class European life science companies in drug development and digital health.
  • Commenting on the first close, Stéphane Verdood, Managing Partner at Vesalius Biocapital IV said:
    "Our successful track record placed us in a strong position to attract high quality investors such as the EIF (European Investment Fund) to Vesalius Biocapital IV.
  • Vesalius Biocapital IV is targeting €150M and will accept new investors on a "rolling closing" basis until the final closing in 2024.

Organon Publishes FY2022 ESG Report Showcasing Progress Toward Global Sustainability Goals

Retrieved on: 
火曜日, 6月 27, 2023
Biotechnology, Professional Services, Other Health, Health, Women, Pharmaceutical, Environmental, Social and Governance (ESG), DEI (Diversity, Equity and Inclusion), Environment, Consumer, Sustainability, United Nations Sustainable Development Group, Promise, Woman, OGN, Sustainable Development Goals, Investment, Water, Biophysical environment, Power, ESG, NYSE, Female, Renewable energy, Birth control, Social, Organon

Organon (NYSE: OGN), a global healthcare company focused on women’s health, today released its 2022-2023 Environmental, Social, and Governance (ESG) Report .

Key Points: 
  • Organon (NYSE: OGN), a global healthcare company focused on women’s health, today released its 2022-2023 Environmental, Social, and Governance (ESG) Report .
  • The report highlights the company’s progress on its comprehensive ESG platform, Her Promise, and its related goals, which are in line with the United Nations Sustainable Development Goals (SDGs).
  • “At Organon, our purpose is fueled by the promise held by the four billion women and girls in the world,” said Kevin Ali, Organon CEO.
  • “Our second ESG report, highlighting the company’s first full year of operations, shows its progress toward important goals.

Organon and CAF, Development Bank of Latin America, Launch First-of-Its-Kind Collaboration to Increase Sustainable Financing in Women’s Health

Retrieved on: 
水曜日, 6月 7, 2023
Women, Finance, Banking, Professional Services, Biotechnology, DEI (Diversity, Equity and Inclusion), General Health, Pharmaceutical, Consumer, Health, United Nations Sustainable Development Group, CAF – Development Bank of Latin America, Woman, CAF, OGN, Government, GDP, Investment, Development finance institution, Risk, MOU, Economic development, NYSE, Drug, Organon

Across the globe, tremendous gaps exist in women’s health that can potentially prevent women and thus economies from achieving their full potential.

Key Points: 
  • Across the globe, tremendous gaps exist in women’s health that can potentially prevent women and thus economies from achieving their full potential.
  • Sustainable financing can advance progress in women’s health by mobilizing capital towards initiatives that might not otherwise receive adequate support like increasing access to sexual and reproductive health education and healthcare services.
  • Sustainable financing is one potential solution to address constrained government budgets while catalyzing healthcarei and socioeconomic progress.
  • By using data, Organon is helping governments understand the value sustainable finance can provide to their people and their economies through health-related investments.

Amarna Therapeutics announces appointment of Dr Henk Streefkerk as new CEO

Retrieved on: 
水曜日, 6月 7, 2023
Streefkerk, Medicine, Heart failure, Clinical trial, CMO, Doctor of Philosophy, Haemophilia B, Actelion, Medical director, Novartis, MD, Patient, Haemophilia, Therapy, Henk, Pharmaceutical industry, Organon

LEIDEN, Netherlands, June 7, 2023 /PRNewswire/ -- Amarna Therapeutics , a privately-held biotechnology company developing transformative gene therapies in a range of rare and prevalent diseases, including Hemophilia B, today announces the appointment of Dr Henk Streefkerk as the Company's new Chief Executive Officer and Medical Director.

Key Points: 
  • LEIDEN, Netherlands, June 7, 2023 /PRNewswire/ -- Amarna Therapeutics , a privately-held biotechnology company developing transformative gene therapies in a range of rare and prevalent diseases, including Hemophilia B, today announces the appointment of Dr Henk Streefkerk as the Company's new Chief Executive Officer and Medical Director.
  • Dr Streefkerk has a distinguished career as CMO of several biotechs, including PIQUR Therapeutics, Cellprotera and Rivia, and brings over a decade of experience working in big pharma including Novartis, Actelion and Organon.
  • "We are very pleased to introduce Henk Streefkerk as our new CEO.
  • Henk will be instrumental in leading Amarna towards the first in human clinical trial," said Thomas Eldered, Chairman of Amarna's supervisory board.

Amarna Therapeutics announces appointment of Dr Henk Streefkerk as new CEO

Retrieved on: 
水曜日, 6月 7, 2023
Streefkerk, Medicine, Heart failure, Clinical trial, CMO, Doctor of Philosophy, Haemophilia B, Actelion, Medical director, Novartis, MD, Patient, Haemophilia, Therapy, Henk, Pharmaceutical industry, Organon

LEIDEN, Netherlands, June 7, 2023 /PRNewswire/ -- Amarna Therapeutics , a privately-held biotechnology company developing transformative gene therapies in a range of rare and prevalent diseases, including Hemophilia B, today announces the appointment of Dr Henk Streefkerk as the Company's new Chief Executive Officer and Medical Director.

Key Points: 
  • LEIDEN, Netherlands, June 7, 2023 /PRNewswire/ -- Amarna Therapeutics , a privately-held biotechnology company developing transformative gene therapies in a range of rare and prevalent diseases, including Hemophilia B, today announces the appointment of Dr Henk Streefkerk as the Company's new Chief Executive Officer and Medical Director.
  • Dr Streefkerk has a distinguished career as CMO of several biotechs, including PIQUR Therapeutics, Cellprotera and Rivia, and brings over a decade of experience working in big pharma including Novartis, Actelion and Organon.
  • "We are very pleased to introduce Henk Streefkerk as our new CEO.
  • Henk will be instrumental in leading Amarna towards the first in human clinical trial," said Thomas Eldered, Chairman of Amarna's supervisory board.

CURE HOSTS "AI FOR GOOD" SUPER SESSION TO MAKE SENSE OF BIG DATA AND HIGH TECH AT 2023 BIO INTERNATIONAL CONVENTION ON JUNE 5

Retrieved on: 
金曜日, 6月 2, 2023
BIO, BCH, Road, Super Session, Exhibition, MB, Disease, Biotechnology, Huntington Avenue, Brigham and Women's Hospital, Health, Boston Convention and Exhibition Center, Research, Doctor of Philosophy, Michigan Biotechnology Institute, EDT, Harvard Medical School, BCEC, BAO, Pandemic, MD, JD, ABC, Coffee, Convention center, Neurology, ESG, Digital, Foreign policy, Ecosystem, AI, Alzheimer's disease, Hospital, Woman, WIB, Pharmaceutical industry, Organon, Cure

NEW YORK, June 2, 2023 /PRNewswire/ -- Cure®, a healthcare innovation campus in New York City, today announced a one-of-a-kind Super Session featuring experts focused on leveraging AI for good as part of the company's presence at the Biotechnology International Convention, the largest global event for the biotech industry, in Boston, MA. from June 5 to 8, 2023.

Key Points: 
  • "The dizzying array of things AI can seemingly do – good, great, and worrisome – has the world of healthcare both excited and overwhelmed.
  • For the BIO Super Session, the panel Cure has gathered will discuss how we can optimally leverage AI and other advanced technologies while mitigating risks," said Cure Chief Executive Officer Seema Kumar.
  • The Cure booth also will host Cure Studios on the Road, capturing highlights and insights from leading biotech executives.
  • The booth will be open 8:00 am to 5:00 pm EDT in the BCEC Ground Level Halls A-C from June 5 to 8, 2023.

APEC CEO Summit USA 2023 To Convene World Leaders and Business Executives to Discuss Creating Economic Opportunity

Retrieved on: 
土曜日, 5月 27, 2023
National Center on Education and the Economy, Private sector, Moody's Investors Service, Meta, FedEx, Uber, Microsoft, APEC, Global health, Visa, Citigroup, Climate change, Moscone Center, Development, Asia-Pacific Economic Cooperation, Mastercard, ExxonMobil, UPS, Merck, Johnson & Johnson, Summit, General Motors, Mobile phone, Management, Boeing, Qualcomm, Amazon, Organon

SEATTLE, May 27, 2023 /PRNewswire-PRWeb/ -- The United States will host the Asia-Pacific Economic Cooperation (APEC) CEO Summit convening more than 1,000 business executives and welcoming key world leaders from across the Asia-Pacific at the Moscone Center in San Francisco from November 15-16, 2023.

Key Points: 
  • SEATTLE, May 27, 2023 /PRNewswire-PRWeb/ -- The United States will host the Asia-Pacific Economic Cooperation (APEC) CEO Summit convening more than 1,000 business executives and welcoming key world leaders from across the Asia-Pacific at the Moscone Center in San Francisco from November 15-16, 2023.
  • The APEC CEO Summit USA 2023 will feature 30+ speakers from the public and private sectors, representing various industries, emerging voices, entrepreneurs, philanthropists, and world leaders from large and small economies.
  • Visit the APEC CEO Summit USA 2023 website for the latest information on the program, newly confirmed speakers, and registration updates.
  • Members of the media are welcome to attend and cover the APEC CEO Summit USA 2023.

PM360 Announces Winners of The Ninth Annual ELITE 100 Awards

Retrieved on: 
火曜日, 5月 16, 2023
Nexium, Data science, Marketing, GoodRx, EVP, Hospira, Associate, Cardinal Health, Patient, McCourt, HR, Disease, Eli Lilly and Company, Constipation, Attention, Snow, Diagnosis, Entrepreneurship, Growth, Digital marketing, Immunology, FAAN, Engagement, Organon, Caregiver, PR, Ironwood Pharmaceuticals, Exception, COVID-19, IBS-C, Health, ELITE, Boehringer Ingelheim, Abdominal pain, Sustainability, ImmunoGen, RN, Bloating, CO, Providers, Glaucoma, Lead, Mirati Therapeutics, Regulatory science, AstraZeneca, HCP, Gastroesophageal reflux disease, Veeva Systems, Novartis, Omeprazole, Management, Pharmaceutical industry, Beauty salon, Generic drug, Esomeprazole, GERD

NEW YORK, May 16, 2023 /PRNewswire/ -- PM360, the premier information resource for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device sectors, today announced the winners of its 9th Annual ELITE 100. The ELITE (Exceptional • Leaders • Innovators • Transformers • Entrepreneurs) represent the most influential people and teams in the healthcare and life sciences industries based on their career accomplishments. Out of more than 500 submissions, 100 winners are selected by the PM360 editorial staff across various categories that span every facet of the industry.

Key Points: 
  • NEW YORK, May 16, 2023 /PRNewswire/ -- PM360, the premier information resource for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device sectors, today announced the winners of its 9th Annual ELITE 100.
  • Out of more than 500 submissions, 100 winners are selected by the PM360 editorial staff across various categories that span every facet of the industry.
  • PM360 also selects one person as the "Uber ELITE," or the individual among the nominees who best personifies the criteria of a PM360 ELITE.
  • McCourt will serve as the keynote speaker at the annual ELITE 100 Awards Event to celebrate this year's winners.